Attached files
| file | filename |
|---|---|
| EX-32.1 - EXHIBIT 32.1 2017 - CUMBERLAND PHARMACEUTICALS INC | a2017-10kxexhibit321.htm |
| EX-31.2 - EXHIBIT 31.2 2017 - CUMBERLAND PHARMACEUTICALS INC | a2017-10kxexhibit312.htm |
| EX-31.1 - EXHIBIT 31.1 2017 - CUMBERLAND PHARMACEUTICALS INC | a2017-10kxexhibit311.htm |
| EX-23.1 - EXHIBIT 23.1 CONSENT OF KPMG 2017 - CUMBERLAND PHARMACEUTICALS INC | a2017-10kxexhibit231consen.htm |
| EX-10.15 - EXHIBIT 10.15 JIMHERMAN 2018 - CUMBERLAND PHARMACEUTICALS INC | a2017-10kxexhibit1015jimhe.htm |
| EX-10.14 - EXHIBIT 10.14 MICHAELBONNER 2018 - CUMBERLAND PHARMACEUTICALS INC | a2017-10kxexhibit1014micha.htm |
| EX-10.13 - EXHIBIT 10.13 LEO PAVLIV 2018 - CUMBERLAND PHARMACEUTICALS INC | a2017-10kxexhibit1013leopa.htm |
| EX-10.12 - EXHIBIT 10.12 MARTINCEARNAL 2018 - CUMBERLAND PHARMACEUTICALS INC | a2017-10kxexhibit1012marti.htm |
| EX-10.11 - EXHIBIT 10.11 AJKAZIMI 2018 - CUMBERLAND PHARMACEUTICALS INC | a2017-10kxexhibit1011ajkaz.htm |
| 10-K - 10-K 2017 - CUMBERLAND PHARMACEUTICALS INC | a2017-10k.htm |
Exhibit 23.2
Consent of Independent Registered Public Accounting Firm
Cumberland Pharmaceuticals Inc.
Nashville, Tennessee
We hereby consent to the incorporation by reference in the Registration Statements on Form S-3 (No. 333-221402) and Form S-8 (No. 333-164376) of Cumberland Pharmaceuticals Inc. of our report dated March 9, 2018, relating to the consolidated financial statements and financial statement schedule which appears in this Form 10-K.
/s/ BDO USA, LLP
Nashville, Tennessee
March 9, 2018